|
1
|
Nørskov MS, Dahl M and Tybjærghansen A:
Genetic variation in GSTP1, lung function, risk of lung cancer and
mortality. J Thorac Oncol. 12:1664–1672. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang JC, Mok T, Han B, Orlando M, Puri T
and Park K: A review of regimens combining pemetrexed with an
epidermal growth factor receptor tyrosine kinase inhibitor in the
treatment of advanced nonsquamous non-small-cell lung cancer. Clin
Lung Cancer. 19:27–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao J, Han J, Xiao H, Qiao J and Han M:
Effect of tea polyphenol compounds on anticancer drugs in terms of
anti-tumor activity, toxicology, and pharmacokinetics. Nutrients.
8:E7622016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oya Y, Mondal A, Rawangkan A, Umsumarng S,
Iida K, Watanabe T, Kanno M, Suzuki K, Li Z, Kagechika H, et al:
Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism
of synergistic enhancement of apoptosis in human lung cancer cells
treated with the combination of a synthetic retinoid, Am80 and
green tea catechin. J Nutr Biochem. 42:7–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hong OY, Noh EM, Jang HY, Lee YR, Lee BK,
Jung SH, Kim JS and Youn HJ: Epigallocatechin gallate inhibits the
growth of MDA-MB-231 breast cancer cells via inactivation of the
β-catenin signaling pathway. Oncol Lett. 14:441–446. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li M, Li JJ, Gu QH, An J, Cao LM, Yang HP
and Hu CP: EGCG induces lung cancer A549 cell apoptosis by
regulating Ku70 acetylation. Oncol Rep. 35:2339–2347. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang L, Tao C, He A and He X:
Overexpression of miR-126 sensitizes osteosarcoma cells to
apoptosis induced by epigallocatechin-3-gallate. World J Surg
Oncol. 12:3832014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng PB, Hu CP, Xiong Z, Yang HP and Li
YY: Treatment with EGCG in NSCLC leads to decreasing interstitial
fluid pressure and hypoxia to improve chemotherapy efficacy through
rebalance of Ang-1 and Ang-2. Chin J Nat Med. 11:245–253. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin J, Huang F, Yi Y, Yin L and Peng D:
EGCG attenuates atherosclerosis through the Jagged-1/Notch pathway.
Int J Mol Med. 37:398–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma S, Deng X, Yang Y, Zhang Q, Zhou T and
Liu Z: The lncRNA LINC00675 regulates cell proliferation,
migration, and invasion by affecting Wnt/beta-catenin signaling in
cervical cancer. Biomed Pharmacother. 108:1686–1693. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xi Z, Si J and Nan J: LncRNA MALAT1
potentiates autophagyassociated cisplatin resistance by regulating
the microRNA30b/autophagyrelated gene 5 axis in gastric cancer. Int
J Oncol. 54:239–248. 2019.PubMed/NCBI
|
|
12
|
Liang H, Zhang C, Guan H, Liu J and Cui Y:
LncRNA DANCR promotes cervical cancer progression by upregulating
ROCK1 via sponging miR-335-5p. J Cell Physiol. 2018 Oct 26;Doi:
10.1002/jcp.27484.
|
|
13
|
Kong X, Duan Y, Sang Y, Li Y, Zhang H,
Liang Y, Liu Y, Zhang N and Yang Q: LncRNA-CDC6 promotes breast
cancer progression and function as ceRNA to target CDC6 by sponging
microRNA-215. J Cell Physiol. 2018 Oct 26;Doi: 10.1002/jcp.27587.
View Article : Google Scholar
|
|
14
|
Delás MJ and Hannon GJ: lncRNAs in
development and disease: From functions to mechanisms. Open Biol.
7:1701212017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng L, Yuan X, Jiang B, Tang Z and Li GC:
LncRNAs: Key players and novel insights into cervical cancer.
Tumour Biol. 37:2779–2788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang ZY, Yang F, Zhang YL, Liu B, Wang M,
Hong X, Yu Y, Zhou YH and Zeng H: LncRNA-ANCR down-regulation
suppresses invasion and migration of colorectal cancer cells by
regulating EZH2 expression. Cancer Biomark. 18:95–104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Han T, Li Y, Sun J, Zhang S, Liu
Y, Shan B, Zheng D and Shi J: The lncRNA SNHG5/miR-32 axis
regulates gastric cancer cell proliferation and migration by
targeting KLF4. FASEB J. 31:893–903. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu H, Zhao H, Zhang L, Xu J, Zhu C, Zhao
H and Lv G: Dandelion root extract suppressed gastric cancer cells
proliferation and migration through targeting lncRNA-CCAT1. Biomed
Pharmacother. 93:1010–1017. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li
TL, Cai JQ, Zhou HH and Zhu YS: H19 lncRNA mediates
17β-estradiol-induced cell proliferation in MCF-7 breast cancer
cells. Oncol Rep. 33:3045–3052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li N, Yu J, Luo A, Tang Y, Liu W, Wang S,
Liu Y, Song Y, Fang H, Chen B, et al: LncRNA and mRNA signatures
associated with neoadjuvant chemoradiotherapy downstaging effects
in rectal cancer. J Cell Biochem. 2018 Oct 15;Doi:
10.1002/jcb.27796.
|
|
21
|
Pan J, Wu X, Wang X, Huang W and Feng Q:
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin
sensitivity in lung cancer cells. Oncotarget. 7:43337–43351.
2016.PubMed/NCBI
|
|
22
|
Wang H, Fang L, Jiang J, Kuang Y, Wang B,
Shang X, Han P, Li Y, Liu M, Zhang Z and Li P: The
cisplatin-induced lncRNA PANDAR dictates the chemoresistance of
ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Cell Death Dis. 9:11032018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Phillips J and Eberwine JH: Antisense RNA
amplification: A linear amplification method for analyzing the mRNA
population from single living cells. Methods. 10:283–288. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gene Ontology Consortium: Gene Ontology
Consortium: Going forward. Nucleic Acids Res. 43:(Database Issue).
D1049–D1056. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Piñero J, Queralt-Rosinach N, Bravo À,
Deu-Pons J, Bauer-Mehren A, Baron M, Sanz F and Furlong LI:
DisGeNET: A discovery platform for the dynamical exploration of
human diseases and their genes. Database (Oxford) 2015. bav0282015.
View Article : Google Scholar
|
|
26
|
Kuhn M, Szklarczyk D, Franceschini A,
Campillos M, von Mering C, Jensen LJ, Beyer A and Bork P: STITCH 2:
An interaction network database for small molecules and proteins.
Nucleic Acids Res. 38:(Database Issue). D552–D556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu Q, Ren S, Lu M, Zhang Y, Zhu D, Zhang X
and Li T: Computational prediction of associations between long
non-coding RNAs and proteins. BMC Genomics. 14:6512013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei R, Mao L, Xu P, Zheng X, Hackman RM,
Mackenzie GG and Wang Y: Suppressing glucose metabolism with
epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth
in preclinical models. Food Funct. 9:5682–5696. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baker KM and Bauer AC: Green tea catechin,
EGCG, suppresses PCB 102-induced proliferation in
estrogen-sensitive breast cancer cells. Int J Breast Cancer 2015.
1635912015.
|
|
32
|
Wang YQ, Lu JL, Liang YR and Li QS:
Suppressive effects of EGCG on cervical cancer. Molecules.
23:E23342018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo KW, Wei Chen, Lung WY, Wei XY, Cheng
BH, Cai ZM and Huang WR: EGCG inhibited bladder cancer SW780 cell
proliferation and migration both in vitro and in vivo via
down-regulation of NF-κB and MMP-9. J Nutr Biochem. 41:56–64. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weng LX, Wang GH, Yao H, Yu MF and Lin J:
Epigallocatechin gallate inhibits the growth of salivary adenoid
cystic carcinoma cells via the EGFR/Erk signal transduction pathway
and the mitochondria apoptosis pathway. Neoplasma. 64:563–570.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jen J, Tang YA, Lu YH, Lin CC, Lai WW and
Wang YC: Oct4 transcriptionally regulates the expression of long
non-coding RNAs NEAT1 and MALAT1 to promote lung cancer
progression. Mol Cancer. 16:1042017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Chen WJ, Gan TQ, Zhang XL, Xie
ZC, Ye ZH, Deng Y, Wang ZF, Cai KT, Li SK, et al: Clinical
significance and effect of lncRNA HOXA11-AS in NSCLC: A study based
on bioinformatics, in vitro and in vivo verification. Sci Rep.
7:55672017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang R, Li P, Zhang G, Lu C, Wang H and
Zhao G: Long non-coding RNA XLOC_008466 functions as an oncogene in
human non-small cell lung cancer by targeting miR-874. Cell Physiol
Biochem. 42:126–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma YC, Li C, Gao F, Xu Y, Jiang ZB, Liu JX
and Jin LY: Epigallocatechin gallate inhibits the growth of human
lung cancer by directly targeting the EGFR signaling pathway. Oncol
Rep. 31:1343–1349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Florespérez A, Marchat LA, Sánchez LL,
Romero-Zamora D, Arechaga-Ocampo E, Ramírez-Torres N, Chávez JD,
Carlos-Reyes Á, Astudillo-de la Vega H, Ruiz-García E, et al:
Differential proteomic analysis reveals that EGCG inhibits HDGF and
activates apoptosis to increase the sensitivity of non-small cells
lung cancer to chemotherapy. Proteomics Clin Appl. 10:172–182.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sadava D, Whitlock E and Kane SE: The
green tea polyphenol, epigallocatechin-3-gallate inhibits
telomerase and induces apoptosis in drug-resistant lung cancer
cells. Biochem Biophys Res Commun. 360:233–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shervington A, Pawar V, Menon S, Thakkar D
and Patel R: The sensitization of glioma cells to cisplatin and
tamoxifen by the use of catechin. Mol Biol Rep. 36:1181–1186. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li Y, Shen X, Wang X, Li A, Wang P, Jiang
P, Zhou J and Feng Q: EGCG regulates the cross-talk between JWA and
topoisomerase IIα in non-small-cell lung cancer (NSCLC) cells. Sci
Rep. 5:110092015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu LY, Ou N and Lu QB: Antioxidant induces
DNA damage, cell death and mutagenicity in human lung and skin
normal cells. Sci Rep. 3:31692013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B,
Liu Y, Liu Y, Yin L, Peng Y, et al: The FOXM1-ABCC5 axis
contributes to paclitaxel resistance in nasopharyngeal carcinoma
cells. Cell Death Dis. 8:e26592017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shanmugam T, Selvaraj M and Poomalai S:
Epigallocatechin gallate potentially abrogates fluoride induced
lung oxidative stress, inflammation via Nrf2/Keap1 signaling
pathway in rats: An in-vivo and in-silico study. Int
Immunopharmacol. 39:128–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yun M, Lee D, Park MN, Kim EO, Sohn EJ,
Kwon BM and Kim SH: Cinnamaldehyde derivative (CB-PIC) sensitizes
chemo-resistant cancer cells to drug-induced apoptosis via
suppression of MDR1 and its upstream STAT3 and AKT signalling. Cell
Physiol Biochem. 35:1821–1830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang G, Zhang Z, Qian H, Chen J, Wang Y,
Chen X, Chen B and Chen Y: (−)-Epigallocatechin-3-gallate inhibits
osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling
pathway in human osteosarcoma cells. J Environ Pathol Toxicol
Oncol. 34:85–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ciccarese C, Massari F, Blanca A, Tortora
G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca
J and Lopez-Beltran A: Tp53 and its potential therapeutic role as a
target in bladder cancer. Expert Opin Ther Targets. 21:401–414.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nuñez NN, Manlove AH and David SS: DNMT1
and cancer: An electrifying link. Chem Biol. 22:810–811. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu L, Liu J, Dai S, Wang X, Wu S, Wang J,
Huang L, Xiao X and He D: Reduced transthyretin expression in sera
of lung cancer. Cancer Sci. 98:1617–1624. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park JY, Kim D, Yang M, Park HY, Lee SH,
Rincon M, Kreahling J, Plass C, Smiraglia DJ, Tockman MS and Kim
SJ: Gene silencing of SLC5A8 identified by genome-wide methylation
profiling in lung cancer. Lung Cancer. 79:198–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tsai CH, Cheng HC, Wang YS, Lin P, Jen J,
Kuo IY, Chang YH, Liao PC, Chen RH, Yuan WC, et al: Small GTPase
Rab37 targets tissue inhibitor of metalloproteinase 1 for
exocytosis and thus suppresses tumour metastasis. Nat Commun.
5:48042014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu CY, Tseng RC, Hsu HS, Wang YC and Hsu
MT: Frequent down-regulation of hRAB37 in metastatic tumor by
genetic and epigenetic mechanisms in lung cancer. Lung Cancer.
63:360–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dötsch MM, Kloten V, Schlensog M, Heide T,
Braunschweig T, Veeck J, Petersen I, Knüchel R and Dahl E: Low
expression of ITIH5 in adenocarcinoma of the lung is associated
with unfavorable patients' outcome. Epigenetics. 10:903–912. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen Y, Cui T, Knösel T, Yang L, Zöller K
and Petersen I: IGFBP7 is a p53 target gene inactivated in human
lung cancer by DNA hypermethylation. Lung Cancer. 73:38–44. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang L, Xiao H, Zhou H, Santiago S, Lee
JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, et al:
Development of transcriptomic biomarker signature in human saliva
to detect lung cancer. Cell Mol Life Sci. 69:3341–3350. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mclemore TL, Adelberg S, Liu MC, McMahon
NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA,
et al: Expression of CYP1A1 gene in patients with lung cancer:
Evidence for cigarette smoke-induced gene expression in normal lung
tissue and for altered gene regulation in primary pulmonary
carcinomas. J Natl Cancer Inst. 82:1333–1339. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Taioli E, Ford J, Trachman J, Li Y,
Demopoulos R and Garte S: Lung cancer risk and CYP1A1 genotype in
African Americans. Carcinogenesis. 19:813–817. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Choi SH, Yang H, Lee SH, Ki JH, Nam DH and
Yoo HY: TopBP1 and Claspin contribute to the radioresistance of
lung cancer brain metastases. Mol Cancer. 13:2112014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Taniguchi H, Takeuchi S, Fukuda K,
Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H and
Yano S: AREG triggered EGFR activation confers in vivo
crizotinib-resistance of EML4-ALK lung cancer and circumvention by
EGFR inhibitors. Cancer Sci. 108:53–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Taron M, Rosell R, Felip E, Mendez P,
Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ
and Maestre J: BRCA1 mRNA expression levels as an indicator of
chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004.
View Article : Google Scholar : PubMed/NCBI
|
